BioSig Technologies to commence first–in-human studies at Mayo Clinic
BioSig Technologies announced that the Company has signed an agreement with Mayo Clinic to conduct First-in-Human studies using the PURE EP™ System. These studies are aimed at validating the safety and efficacy of the PURE EP™ System during mapping and ablation procedures in the cardiac EP lab. December 06, 2018